報價延遲最少15分鐘:2026/01/08 17:09 EST
盤後時段
|
||||
|
15.33 
|
|
|
常規時段 (已結束)
|
|
|
|
|
||||||||||||
|
|
|
|
|
15.33
|
|
|
| 價值評估 |
|
盈利(現時/預測)
0.56/0.62
|
|
企業價值
2.18B
|
| 資產負債 |
|
每股賬面淨值
2.77
|
| 現金流量 |
|
現金流量率
0.05
|
| 損益表 |
|
收益
235.13M
|
|
每股收益
1.20
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmunediseases. |
